Abstract:

From author's abstract: "Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical therapy. This article reviews the data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how this treatment should be combined with surgical resection (when possible) to optimize patient outcomes. Although surgical resection remains the mainstay of treatment for these tumors, patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. In these patients the drug should be continued until progression, intolerance, or the patients are rendered resectable. Patients with advanced GIST who are successfully resected after imatinib treatment should be placed back on imatinib postoperatively". http://www.dovepress.com/oncotargets-and-therapy-journal

Rights:

Open Access, Full Text Article by Dovepress Free PDF downloads http://www.dovepress.com/oncotargets-and-therapy-journal

Download:

Cancers_Early_ImatinibImaging151p.pdf
oncotargets-and-therapy-journal

Links:

No messages.